Product Launch and Distribution


Product Launch & Distribution Meeting Product Launch and Distribution

Having successfully partnered in the launch of 15 significant orphan and niche drug products into the EU market over the last 3 years, Almac is the industry leader for Product Launch and Distribution.

The European marketplace presents a variety of challenges, from numerous official working languages to complex regulatory frameworks. With the knowledge and expertise of our professional Product Supply Managers, we can ensure your product launch runs smoothly.

We have supported many of the industry’s recent first in class, innovative orphan drug launches in areas such as Cystic Fibrosis, Muscular Dystrophy, Hemolysis and Short Bowel Syndrome.

Our Dedicated Product Supply Team

Our dedicated product supply team are experts in navigating market requirements and supporting client partners to successfully launch their orphan / niche drug products. They have extensive practical experience of launching products into the marketplace and manage a multidisciplinary project team in quality, packaging design, regulatory and distribution, ensuring milestones are met and that your market entry strategy is successful.

Almac Product Launch and Distribution Timeline

Our Services

In our experience, it’s never too early to start to think about the launch of your drug product. We take pride in our ability to support our clients with varying time frames, from as far as 24 months before submission of their MAA to those with shorter time frames, post submission.

Having successfully supported the launch of 15 high value niche and orphan drugs over the past three years, we can provide expert guidance on launch strategy and offer the following tailored solutions:

Named Patient Supply and Early Access Programs (Click to Expand)

Meeting Patient Needs

Named patient supply programs have many benefits for both the patient and your organisation. For those patients that have participated in your clinical trial and have benefited from treatment, this program can provide continued access to the drug product after the clinical trial. This type of supply can also facilitate market penetration by enabling physicians and patients in Europe to access drug products that have been approved by the EMA, but have yet to be launched commercially in the individual member states.
While pre-launch access is permitted by EU legislation, Named Patient Programs are governed by the individual member states, which have their own regulations regarding access and specific requirements for supply.
We have successfully developed, implemented and managed Named Patient Supply programs in over 30 markets. Our expert distribution and product supply teams can help alleviate some of the unknown logistical and regulatory pathways, allowing for a quicker supply process.

QP Declaration, Site of Release and Finished Product Market Release (Click to Read More)

Underpinning Quality

Nominating a Qualified Person (QP) for the release of your drug product to market is a requirement when submitting your MAA. Our experienced QP’s can act as an extension to your team, putting in place relevant quality agreements between all manufacturing sites, and taking responsibility for product quality and market release.

EU Import Testing and QP Release (Click to Read More)

Expert Guidance on EU Import Testing and QP Release for Over 40 Years

If your drug product is manufactured outside of the EU, it must be fully tested by a lab within the EU, to an approved EU specification. Medicinal products cannot be released for sale or supply until they have received certification by a Qualified Person (QP) and a batch must be fit for purpose and be processed and handled in accordance with Manufacturing Authorisation (MA).

With state-of-the-art analytical laboratories at the ready and employing over 250 analysts, we are able to provide EU import testing for bulk product. We test both small and large molecules and our dedicated microbiological analyst team can address all of your biological product-testing needs.

We hold a Manufacturers Import License as required by EU legislation and employ a dedicated team of five Qualified Persons (QPs) to monitor and certify the release of drug products to the marketplace.

Regionalised Packaging (Click to Read More)

Reduce Your Stock Holding and Minimize Costs

To minimise your stock holding and maximise it’s flexibility, we can assist you in developing regionalisation strategies (grouping markets into multi-language/country packs). By engaging our expert forethought and guidance on regional packs, we help to ensure that, where appropriate, smaller markets can be served without committing stock to orders that may never arise.
Our late stage customisation and just-in-time processing of regionalised packs results in one pack being available for as many as 5 markets. Processing drug products just in time and tailoring your stock to the market provides increased flexibility, reduced stock holding, minimised costs and reduced lead-time to the end-user.

Order and Financial Management (Click to Read More)

Enabling a Shorter, More Flexible and Fully Integrated Drug Product Supply Chain

We receive direct orders 24/7 from registered pharmacists via a secure web based Product Order Portal (POP) or alternatively through a dedicated email, multilingual telephone or fax-based channels. This ensures a smooth, rapid delivery.

Utilising an integrated customer billing application, we can also offer client invoicing, monitoring and reporting of customer payments, debtor follow up and account management.
To receive a demonstration of our comprehensive online ordering system, please get in touch.

End-User Distribution (Click to Read More)

Simplifying Your Supply Chain

Processing product orders received directly from hospitals and pharmacies via secure online portal, phone and fax, we distribute to the end-user and then invoice for payment. We can develop and qualify suitable packaging configurations (including cold chain and controlled ambient shipments) or utilise temperature-controlled vehicles, which are supported by our data recording and tracking systems.

Our dedicated logistics team work with our distribution partners to ensure your drug reaches the pharmacy in optimum condition within 24-48 hours of an order being received. To make the distribution process as simple as possible, we can also assist with the management of all necessary import/export documentation and customs clearance.


The Almac TouchTM
: By integrating all of your pharmaceutical and distribution needs into a single supply team, you will minimise your effort and maximise your return.

Click Thumbnail to Download Infographic

Orphan Drug Product Launch and Distribution

 

 

 

 

 


More Details

Experience
Product Supply Management
End-to-End Product Supply

Experience

Broad Expertise – From Development to Commercialisation

Almac is an FDA and MHRA approved outsourcing partner to the global pharmaceutical and biotechnology industries. We are a technology-rich and innovative company with over 40 years’ expertise in the development and manufacture of solid, oral dose products and the labelling and packaging of sterile forms. We have the most comprehensive range of integrated drug development services available to the pharmaceutical/biotech industry. Our service offering ranges from product development to clinical batch production and manufacturing and packaging to customised commercial product launch support services.

Our commercial product launch team provides an integrated one-stop-shop service. From product import analysis to in-country distribution, we specialise in orphan drug launches. Our team of experts can manage your product’s entry into the EU market from named patient supply through to launch and into commercial supply. We have proudly assisted our clients with the launch of their orphan drugs and are partners to some of the most innovative and market leading orphan drug companies.


Product Supply Management

Full Service Coordination of All Your Launch Activities

To ensure our commitment to quality, all launch activities are managed by an experienced Product Supply Manager who leads a multi-disciplinary team of experts in quality assurance, quality control, packaging design, production and logistics. This helps secure a timelier and better coordinated launch experience.

The progress of your launch is continuously monitored by means of routine calls and meetings and the use of a live project plan. The entire project team regularly reviews this plan in order to stay well informed and communicate out on the status and any next steps.

Outstanding service continues even after your drug has been successfully launched, as your appointed Product Supply Manager will continue assisting you with your ongoing commercial supply needs.


End-to-End Product Supply

With EU and FDA commercial manufacturing and packaging facilities we are able to support your product launch from commercial manufacturing of drug product, bespoke packaging right through to end-user distribution. Our truly integrated “one stop shop solution” combines our cGMP pharmaceutical operations with 3PL distribution channels direct to hospital or pharmacy. By integrating these services our client partners meet launch timelines, mitigate risk, and reduce overall product costs.




More Details

Experience
Product Supply Management
End-to-End Product Supply

Experience

Broad Expertise – From Development to Commercialisation

Almac is an FDA and MHRA approved outsourcing partner to the global pharmaceutical and biotechnology industries. We are a technology-rich and innovative company with over 40 years’ expertise in the development and manufacture of solid, oral dose products and the labelling and packaging of sterile forms. We have the most comprehensive range of integrated drug development services available to the pharmaceutical/biotech industry. Our service offering ranges from product development to clinical batch production and manufacturing and packaging to customised commercial product launch support services.

Our commercial product launch team provides an integrated one-stop-shop service. From product import analysis to in-country distribution, we specialise in orphan drug launches. Our team of experts can manage your product’s entry into the EU market from named patient supply through to launch and into commercial supply. We have proudly assisted our clients with the launch of their orphan drugs and are partners to some of the most innovative and market leading orphan drug companies.


Product Supply Management

Full Service Coordination of All Your Launch Activities

To ensure our commitment to quality, all launch activities are managed by an experienced Product Supply Manager who leads a multi-disciplinary team of experts in quality assurance, quality control, packaging design, production and logistics. This helps secure a timelier and better coordinated launch experience.

The progress of your launch is continuously monitored by means of routine calls and meetings and the use of a live project plan. The entire project team regularly reviews this plan in order to stay well informed and communicate out on the status and any next steps.

Outstanding service continues even after your drug has been successfully launched, as your appointed Product Supply Manager will continue assisting you with your ongoing commercial supply needs.


End-to-End Product Supply

With EU and FDA commercial manufacturing and packaging facilities we are able to support your product launch from commercial manufacturing of drug product, bespoke packaging right through to end-user distribution. Our truly integrated “one stop shop solution” combines our cGMP pharmaceutical operations with 3PL distribution channels direct to hospital or pharmacy. By integrating these services our client partners meet launch timelines, mitigate risk, and reduce overall product costs.